Company profile: Gilupi
1.1 - Company Overview
Company description
- Provider of medical devices and diagnostic solutions for in vivo isolation and analysis of rare circulating cells from blood. Offers GILUPI CellCollector for enriching circulating tumor cells, liquid biopsy sampling, immunofluorescence microscopy, NuPLex technology for RNA detection, and next-generation sequencing for genetic analysis.
Products and services
- GILUPI CellCollector®: Clinical-grade device that enriches circulating tumor cells directly from the bloodstream, enabling in vivo isolation for diagnostic use in rare cell detection
- NuPLex® Technology: High-accuracy method that detects RNA in tumor cells, enabling genetic analysis of circulating tumor cells for precise characterization
- Liquid Biopsy: Non-invasive method that samples circulating DNA, RNA, or tumor cells from blood, offering an alternative to traditional tissue biopsies for molecular assessment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Gilupi
Immix Biopharma
HQ: United States
Website
- Description: Provider of oncology and inflammation-driven therapeutics and platforms, including NXC-201, a BCMA-targeted CAR-T in Phase 1b/2a for relapsed/refractory AL amyloidosis and multiple myeloma, and IMX-110, a tissue-specific therapy in Phase 1b/2a for advanced solid tumors. Develops the N-GENIUS Cell Therapy Platform (EXPAND) and SMARxT platform, plus TME and Immune Normalization technologies to enhance CAR-T and address pathologic inflammation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immix Biopharma company profile →
GEDiCube
HQ: The Netherlands
Website
- Description: Provider of AI/ML multi-omics analytics for biomarker discovery, early cancer detection, and treatment monitoring. Offerings include the GEDi Cube platform leveraging epigenomics, transcriptomics, metabolomics, genomics and clinical data; 2600+ biomarker panels for detection and patient stratification; liquid biopsy diagnostics; an explainable AI engine; and non-toxic therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GEDiCube company profile →
Perspective Therapeutics
HQ: United States
Website
- Description: Provider of radiopharmaceutical cancer theranostics and targeted alpha-particle radiotherapy, including Pb-203 diagnostics and Pb-212 treatment via targeting peptides. Offers clinical programs VMT-α-NET for neuroendocrine tumors and VMT01 for metastatic melanoma, and a proprietary Pb-212 isotope generator to secure key isotopes for clinical trials and commercial operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Perspective Therapeutics company profile →
Crescent Biopharma
HQ: United States
Website
- Description: Provider of novel precision-engineered biologics targeting verified biology to treat solid tumors, originating from discoveries at Paragon Therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Crescent Biopharma company profile →
Blueprint Medicines
HQ: United States
Website
- Description: Provider of precision, targeted therapies for cancer and blood disorders, using genetic insights to design treatments tailored to specific mutations. Portfolio includes avapritinib (KIT/PDGFRA) for GIST and systemic mastocytosis; elenestinib for indolent systemic mastocytosis; BLU-222, a CDK2 inhibitor for HR+ HER2- breast cancer and CCNE1-aberrant tumors; fidrisertib, an ALK2 inhibitor for fibrodysplasia ossificans progressiva.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Blueprint Medicines company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Gilupi
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Gilupi
2.2 - Growth funds investing in similar companies to Gilupi
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Gilupi
4.2 - Public trading comparable groups for Gilupi
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →